Loading...

Medcomtech

BME:MED
Snowflake Description

Adequate balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MED
BME
€16M
Market Cap
  1. Home
  2. ES
  3. Healthcare
Company description

Medcomtech, S.A. distributes products in the areas of orthopedic surgery, traumatology, neurosurgery, and anesthesia worldwide. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
  • Medcomtech has significant price volatility in the past 3 months.
MED Share Price and Events
7 Day Returns
-4.7%
BME:MED
0.9%
Europe Healthcare
-0.3%
ES Market
1 Year Returns
-57.3%
BME:MED
-22.5%
Europe Healthcare
-6%
ES Market
MED Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medcomtech (MED) -4.7% -8.9% -36.6% -57.3% -79.2% -88.3%
Europe Healthcare 0.9% -2.5% -2.2% -22.5% -6.1% 41.6%
ES Market -0.3% -0.6% -1.5% -6% 12.9% -19.1%
1 Year Return vs Industry and Market
  • MED underperformed the Healthcare industry which returned -22.5% over the past year.
  • MED underperformed the Market in Spain which returned -6% over the past year.
Price Volatility
MED
Industry
5yr Volatility vs Market

Value

 Is Medcomtech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Medcomtech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Medcomtech.

BME:MED Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year ES Government Bond Rate 1.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BME:MED
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year ES Govt Bond Rate 1.5%
Equity Risk Premium S&P Global 8.2%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.638 (1 + (1- 25%) (63.21%))
0.96
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.53% + (0.96 * 8.18%)
9.38%

Discounted Cash Flow Calculation for BME:MED using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Medcomtech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BME:MED DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 9.38%)
2019 3.57 Est @ 104.33% 3.26
2020 6.19 Est @ 73.49% 5.18
2021 9.41 Est @ 51.9% 7.19
2022 12.87 Est @ 36.79% 8.99
2023 16.24 Est @ 26.21% 10.37
2024 19.30 Est @ 18.8% 11.27
2025 21.93 Est @ 13.62% 11.71
2026 24.12 Est @ 9.99% 11.77
2027 25.91 Est @ 7.45% 11.56
2028 27.38 Est @ 5.67% 11.17
Present value of next 10 years cash flows €92.48
BME:MED DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €27.38 × (1 + 1.53%) ÷ (9.38% – 1.53%)
€354.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €354.04 ÷ (1 + 9.38%)10
€144.45
BME:MED Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €92.48 + €144.45
€236.93
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €236.93 / 12.90
€18.36
BME:MED Discount to Share Price
Calculation Result
Value per share (EUR) From above. €18.36
Current discount Discount to share price of €1.23
= -1 x (€1.23 - €18.36) / €18.36
93.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Medcomtech is available for.
Intrinsic value
>50%
Share price is €1.23 vs Future cash flow value of €18.36
Current Discount Checks
For Medcomtech to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Medcomtech's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Medcomtech's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medcomtech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medcomtech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BME:MED PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.68
BME:MED Share Price ** BME (2019-06-17) in EUR €1.23
Europe Healthcare Industry PE Ratio Median Figure of 61 Publicly-Listed Healthcare Companies 21.2x
Spain Market PE Ratio Median Figure of 138 Publicly-Listed Companies 17.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medcomtech.

BME:MED PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:MED Share Price ÷ EPS (both in EUR)

= 1.23 ÷ -0.68

-1.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medcomtech is loss making, we can't compare its value to the Europe Healthcare industry average.
  • Medcomtech is loss making, we can't compare the value of its earnings to the Spain market.
Price based on expected Growth
Does Medcomtech's expected growth come at a high price?
Raw Data
BME:MED PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Industry PEG Ratio Median Figure of 38 Publicly-Listed Healthcare Companies 1.42x
Spain Market PEG Ratio Median Figure of 79 Publicly-Listed Companies 1.6x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medcomtech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medcomtech's assets?
Raw Data
BME:MED PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.31
BME:MED Share Price * BME (2019-06-17) in EUR €1.23
Europe Healthcare Industry PB Ratio Median Figure of 74 Publicly-Listed Healthcare Companies 1.8x
Spain Market PB Ratio Median Figure of 185 Publicly-Listed Companies 1.68x
BME:MED PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:MED Share Price ÷ Book Value per Share (both in EUR)

= 1.23 ÷ 0.31

4.02x

* Primary Listing of Medcomtech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medcomtech is overvalued based on assets compared to the Europe Healthcare industry average.
X
Value checks
We assess Medcomtech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Medcomtech has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Medcomtech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medcomtech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.5%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medcomtech expected to grow at an attractive rate?
  • Unable to compare Medcomtech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Medcomtech's earnings growth to the Spain market average as no estimate data is available.
  • Unable to compare Medcomtech's revenue growth to the Spain market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BME:MED Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 12.5%
Europe Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
Spain Market Earnings Growth Rate Market Cap Weighted Average 7.8%
Spain Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BME:MED Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BME:MED Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 24 3 -8
2018-09-30 26 4 -8
2018-06-30 28 5 -6
2018-03-31 28 3 -4
2017-12-31 29 2 -3
2016-12-31 28 1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Medcomtech is high growth as no earnings estimate data is available.
  • Unable to determine if Medcomtech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BME:MED Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medcomtech Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:MED Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.68
2018-09-30 -0.60
2018-06-30 -0.58
2018-03-31 -0.40
2017-12-31 -0.24
2016-12-31 -0.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medcomtech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Medcomtech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Medcomtech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Medcomtech's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Medcomtech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medcomtech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Medcomtech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medcomtech's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medcomtech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medcomtech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medcomtech's 1-year growth to the Europe Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Medcomtech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medcomtech Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:MED Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 24.35 -8.50 14.88
2018-09-30 26.06 -7.54 15.49
2018-06-30 27.76 -6.31 16.10
2018-03-31 28.17 -4.35 16.36
2017-12-31 28.57 -2.68 16.61
2016-12-31 27.75 -2.74 16.16
2015-12-31 25.47 -1.45 15.58
2015-06-30 22.08 0.50 11.00
2015-03-31 21.18 0.54 10.76
2014-12-31 20.27 0.57 10.53
2014-09-30 19.75 0.64 9.75
2014-06-30 19.22 0.70 8.98
2014-03-31 18.82 0.73 8.94
2013-12-31 18.42 0.77 8.90
2013-09-30 17.81 0.72 8.50
2013-06-30 17.20 0.68 8.09
2013-03-31 16.94 0.52 8.20
2012-12-31 16.69 0.35 8.30
2012-09-30 15.90 -0.06 8.63
2012-06-30 15.11 -0.48 8.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medcomtech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medcomtech has efficiently used its assets last year compared to the Europe Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medcomtech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medcomtech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medcomtech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Medcomtech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medcomtech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medcomtech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medcomtech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medcomtech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medcomtech Company Filings, last reported 5 months ago.

BME:MED Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 0.82 10.03 1.06
2018-09-30 0.82 10.03 1.06
2018-06-30 1.42 13.30 0.46
2018-03-31 1.42 13.30 0.46
2017-12-31 6.23 13.57 0.54
2016-12-31 5.97 18.22 0.57
2015-12-31 9.88 16.96 0.96
2015-06-30 16.01 10.14 1.85
2015-03-31 16.01 10.14 1.85
2014-12-31 15.44 9.66 1.64
2014-09-30 15.44 9.66 1.64
2014-06-30 16.16 7.40 1.40
2014-03-31 16.16 7.40 1.40
2013-12-31 15.51 6.96 1.94
2013-09-30 15.51 6.96 1.94
2013-06-30 15.48 6.20 1.95
2013-03-31 15.48 6.20 1.95
2012-12-31 14.71 7.51 0.98
2012-09-30 14.71 7.51 0.98
2012-06-30 12.41 11.35 4.57
  • Medcomtech's level of debt (1224%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (44.9% vs 1224% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Medcomtech has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Medcomtech has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -104.9% per year.
X
Financial health checks
We assess Medcomtech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medcomtech has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Medcomtech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medcomtech dividends.
If you bought €2,000 of Medcomtech shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medcomtech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medcomtech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BME:MED Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 46 Stocks 1.7%
Spain Market Average Dividend Yield Market Cap Weighted Average of 77 Stocks 4.4%
Spain Minimum Threshold Dividend Yield 10th Percentile 1.2%
Spain Bottom 25% Dividend Yield 25th Percentile 2.2%
Spain Top 25% Dividend Yield 75th Percentile 5.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BME:MED Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2014-04-03 0.101 1.367
2014-03-24 0.101 0.753
2014-03-20 0.101 0.746

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medcomtech has not reported any payouts.
  • Unable to verify if Medcomtech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medcomtech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medcomtech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medcomtech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medcomtech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medcomtech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Medcomtech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Juan Manas
CEO Bio

Mr. Juan Sagales Manas serves as the Chairman of the Board, Chief Executive Officer and President at Medcomtech S.A.

CEO Compensation
  • Insufficient data for Juan to compare compensation growth.
  • Insufficient data for Juan to establish whether their remuneration is reasonable compared to companies of similar size in Spain.
Management Team

Juan Manas

TITLE
Chairman of the Board

Mounir Remili

TITLE
Operations Director

Alejandro Roca de Vinals Delgado

TITLE
Senior Vice-President

Jordi Llobet Perez

TITLE
Non-Board Secretary
Board of Directors

Juan Manas

TITLE
Chairman of the Board

Alejandro Roca de Vinals Delgado

TITLE
Senior Vice-President

J. De Luis Y Lorenzo

TITLE
Director

Josep Maria Coronas Guinart

TITLE
Director

Nicolas Ayuso Moragas

TITLE
Director

Salvador Torrens Iglesias

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Medcomtech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medcomtech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Those Who Purchased Medcomtech (BME:MED) Shares Five Years Ago Have A 86% Loss To Show For It

That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. … Over five years, Medcomtech grew its revenue at 11% per year. … The truth is that the growth might be below expectations, and investors are probably worried about the continual losses.

Simply Wall St -

Who Owns Medcomtech SA (BME:MED)?

Today, I will be analyzing Medcomtech SA’s (BME:MED) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine MED's ownership structure in more detail.

Simply Wall St -

Who Are Medcomtech SA.'s (BME:MED) Major Shareholders?

With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in MED should also look at another important group of investors: private companies, with a stake of 24.25%, who are primarily invested because of strategic and capital gain interests. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: Institutional ownership level and composition in MED is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Medcomtech SA.'s (BME:MED) Earnings Dropped -89.03%, Did Its Industry Show Weakness Too?

Today I will take a look at Medcomtech SA.'s (BME:MED) most recent earnings update (31 December 2016) and compare these latest figures against its performance over the past few years, as well as how the rest of the healthcare industry performed. … Check out our latest analysis for Medcomtech Was MED's recent earnings decline indicative of a tough track record? … I prefer to use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data.

Simply Wall St -

What You Must Know About Medcomtech SA.'s (BME:MED) Financial Strength

Moreover, MED has generated €931.84K in operating cash flow over the same time period, resulting in an operating cash to total debt ratio of 5.12%, indicating that MED’s debt is not appropriately covered by operating cash. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: MED’s debt and cash flow levels indicate room for improvement. … Its cash flow coverage of less than a quarter of debt means that operating efficiency could be an issue.

Simply Wall St -

Company Info

Description

Medcomtech, S.A. distributes products in the areas of orthopedic surgery, traumatology, neurosurgery, and anesthesia worldwide. The company offers orthopedic surgery, trauma, and neurosurgery products for spine, hip-femur-knee, biologics, and upper and lower limbs, as well as biologics and cements. It also provides anesthesia products in the area of airway management. The company was founded in 2001 and is based in Barcelona, Spain.

Details
Name: Medcomtech, S.A.
MED
Exchange: BME
Founded: 2001
€15,873,125
12,904,980
Website: http://www.medcomtech.es
Address: Medcomtech, S.A.
Edificio Brasil,
Viladecans Business Park,
Barcelona,
Catalonia, 08840,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME MED Registered Shares Bolsas y Mercados Espanoles ES EUR 25. Mar 2010
Number of employees
Current staff
Staff numbers
130
Medcomtech employees.
Industry
Health Care Distributors
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 21:41
End of day share price update: 2019/06/17 00:00
Last earnings filing: 2019/05/02
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.